Aurobindo Pharma Ltd. — Capital/Financing Update 2018

Nov 13, 2018

November 12, 2018

To	To
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Sandra Kurla Complex, Sandra (E),	25th floor, Dalal Street,
MUMBAI· 400 051	MUMBAI • 400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

Sub: Outcome of the Board Meeting held on 12th November, 2018.

The Soard of Directors of the Company at its meeting held on 12th November, 2018 has inter alia, transacted the following business:

• 1. Approved the Un-audited Financial Results of the Company for the second Quarter and half year ended 30th September, 2018 pursuant to Regulation 33 of SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results of the Company along with the Limited Review Reports of the Statutory Auditors of the Company.
• 1. Approved Interim Dividend @125% i.e RS.1.25/- (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2018-19. The Company has fixed 22nd November, 2018 as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before 30th November, 2018.
• 1. Our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from 'Advent Pharmaceuticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The disclosure pursuant to Regulation 30 of the SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.

The Soard meeting commenced at 4.00 p.m and concluded at 6.30 p.m.

Yours faithfully, For AUROBINDO PHARMA LIMITED

~(L,_ B.AdiReddy Company Secretary

Enclosures: as above.

(CIN: l24239TG1986PlC015190) AUROBINDO PHARMA LIMITED PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. II, Survey No.9, Hi·tech City, Kondapur, Hyderabad · 500 084 T.S., INDIA Tel: +91 406672 5000 {1200 Fax: +91 4067074059 Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad · 500 038 T.S., INDIA Tel : +91 4023736370 Fax: +91 4023747340, Email: info@aurobindo.com

Annexure· A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015
a) Name of the target entity, details in brief such assize, turnover etc.	Name of the Target:Acquisition of certain R & 0 assets from AdventPharmaceuticals pty Ltd., Australia, which is into thebusiness of R & 0 in complex specialty generics.No revenues generated during 12 months periodending September 2018, since it is engaged in R & 0Activity.
b) Whether the acquisition would fall within relatedpromoter /party transaction(s)whethertheandpromoter group/ group companies have any interest inthe entity being acquired? If yes, nature of interest anddetails thereof and whether the same is done at "arms-length"	Advent Pharmaceuticals pty Ltd. is an independentcompany registered in Australia.The promoter/ promoter group/ group companies ofAurobindo Pharma Limned have no interest in theTarget so the acquisition would not fall within relatedparty transaction(s).
c) Industry to which the entity being acquired belongs;	Pharmaceuticals -R & 0 in Complex SpecialtyGenerics
d) Objects and effects of acquisition (including but notlimited to, disclosure of reasons for acquisition of targetentity, if its business is outside the main line ofbusiness of the listed entity)	• Acquisition provides an opportunity to acquire assetsthat would be used for specialty generics business.• Acquisition will lead to enhancement of R &0capabilities in complex specialty generics• No sales for first 12 months is expected
e) Brief details of any governmental or regulatoryapprovals required for the acquisition;	Closing of the transaction is subject to clearance fromState Authority for Licensing.
o Indicative timeperiod for completion of the acquisition	January 2019
g) Nature of consideration -whether cash considerationor share swap and details of the same	Cash Consideration
h) Cost of acquisition or the price at which the sharesare acquired	USO 12.5 million.
i) Percentage of shareholding / control acquired and / ornumber of shares acquired	No shares were acquired.The Company acquires a product under developmentand its related assets that are being used for R & 0 inspecialty generics through AuroScience Pty Limited,Melbourne, a 100% subsidiary of Aurobindo PharmaUSA Inc., USA, which in turn is 100% subsidiary ofAurobindo Pharma Limited, India.
j) Brief background about the entity acquired in terms ofproducts/lineofbusinessofacquired,dateincorporation, history of last 3 years turnover, country inwhich the acquired entity has presence and any othersignificant information (in brie0	The acquisition is a product under development andcertainrelatedbusinessassetsfromAdventPharmaceuticals Pty Ltd.There was no sale during the last three years.

PHARMA LIMITED * HY') · * (CIN: L24239TG1986PLC015190) AUROBINDO PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. 11, Survey No.9, Hi-tech City, Kondapur, Hyderabad· 500 084 T.S., INDIA Tel: +91 406672 5000 {1200 Fax: +91 4067074059 Rand. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad· 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 4023747340, Email: info@aurobindo.com